ANIP Stock — ANI Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$76.14

Market cap

$1,748.1M

Cash

$360.2M

Enterprise value

$1,668.0M

Balance sheet

Cash	$360.2M
Debt	$280.1M
Net cash	$80.1M
Enterprise value	$1,668.0M
Basic shares	21.9M shares
Fully diluted shares	27.3M shares
Fully diluted market cap	$2,076.1M
Cash per share	$16.45

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ANIP daily closes…

Loading price history…

Pipeline assets

Purified Cortrophin Gel (Repository Corticotropin Injection USP)

Approved · Active

Target ACTH

Indications

Acute gouty arthritis flares (Approved)

Status note Approved commercial product; FDA approved a prefilled syringe format on May 28, 2025. Commercial launch announced January 24, 2022.

ILUVIEN (fluocinolone acetonide intravitreal implant)

Approved · Active Modality: intravitreal implant

Partnerships Licensed from EyePoint (via Alimera collaboration agreement; $75M upfront); Alimera patent rights limited to diseases of the human eye in Europe/Middle East/Africa and certain other territories

Indications

Diabetic macular edema (DME) (Approved)
Chronic non-infectious uveitis affecting the posterior segment (NIU-PS) (Approved)

Status note Approved product; FDA approved an expanded label to include chronic NIU-PS in addition to DME.

Novel pitolisant formulation

Stage not disclosed · Active

Partnerships Co-exclusive license with Harmony/Novitium to develop the formulation; company earns low-single digit royalties on net sales of pitolisant-based products

Indications

Broad central nervous system indications (outside sleep/wake) (Stage not disclosed)

Status note Early-stage development intent only; filing states no clinical stage. Company is primarily a commercial generics/branded pharma; the 10-Q carries no clinical-stage pipeline beyond this candidate.

Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Ikarian Capital	272,085	+125,000	3.69%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ANIP — ANI Pharmaceuticals Inc.

Balance sheet

Price history

Pipeline assets

Institutional holders